Jacquelyn Kilbourne

Institute of Animal Sciences — China

Biochemistry, Genetics and Molecular Biology · Life Sciences

22h-index1.6kcitations98works8.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(51), Cancer Research and Treatments(33), Viral Infectious Diseases and Gene Expression in Insects(19), interferon and immune responses(13), Transgenic Plants and Applications(12)

Publications98 total

Squamous cell carcinoma antigen-1/SerpinB3 is an endogenous skin injury response element
Proceedings of the National Academy of Sciences·2025· 1 citedOpen Access
Skin repair and infection control in diabetic, obese mice using bioactive laser-activated sealants
Biomaterials·2024· 5 citedOpen Access
Bioactive nanomaterials kickstart early repair processes and potentiate temporally modulated healing of healthy and diabetic wounds
Biomaterials·2024· 19 citedOpen Access
FIGURE 2 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Table S1 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 5 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Figure S1 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 7 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 6 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Figure S2 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Figure S4 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Figure S1 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Figure S3 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Figure S2 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
Supplementary Figure S5 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 4 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 8 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 8 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 1 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
FIGURE 6 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Jordan R. Yaron(11), Kenneth Lowe(10), Kaushal Rege(10), Hugh S. Mason(9), Tsafrir S. Mor(8), Deepanjan Ghosh(8), Juliane Daggett-Vondras(7), Masmudur M. Rahman(6), Qiang Chen(5), Andrew G. Diamos(5), Alexandra Lucas(5), Charles J. Arntzen(4), Brian C. Geyer(4), Jung Keun Lee(4), Shelley E. Haydel(4), Grant McFadden(4), Mary D. Pardhe(4), Sudhakar Godeshala(4), Rajeshwar Nitiyanandan(4), Michelle Burgin(4)